Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells

Virology

Volumn 281, Issue 2, 2001, Pages 231-238

  Šmahel, Michal ^a   Šíma, Pavel ^a   Ludvíková, Viera ^a   Vonka, Vladimír ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

DNA vaccine; E7 oncogene; Human papillomaviruses; Mutagenesis

Indexed keywords

DNA VACCINE; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FUSION GENE; GENE GUN; GENE THERAPY; IMMUNOGENICITY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; ONCOGENE; PLASMID; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS STRAIN; WART VIRUS;

ANIMALIA; PAPILLOMAVIRUS;

EID: 0035866607     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0794     Document Type: Article

References (47)

1. Identification of H-2Kb binding and immunogenic peptides from human papilloma virus turnout antigens E6 and E7
2. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
3. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer
4. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16
5. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope
6. Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA
7. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs
8. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16
9. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen
10. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection
11. A point mutational analysis of human papillomavirus type 16 E7 protein
12. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization
13. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
14. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16
15. Potential strategies utilised by papillomavirus to evade host immunity
16. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations
17. The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia
18. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
19. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX
20. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses
21. The central role of CD4(+) T cells in the antitumor immune response
22. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
23. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific
24. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene
25. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens
26. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
27. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus turnout antigen, E6
28. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7
29. Chimeric papillomavirus-like particles
30. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
31. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway
32. Gene gun-based nucleic acid immunization: Elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA
33. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery
34. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus poi peptide increases complex stability and in vitro immunogenicity
35. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein
36. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection
37. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity
38. Vesicular stomatitis virus antigenic octapeptide N52-N59 is anchored into the groove of the H-2Kb molecule by the side chains of three amino acids and the main-chain atoms of the amino terminus
39. DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes and the activated ras oncogene
40. Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge
41. Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge
42. Toward the development of DNA vaccines
43. The current status of therapeutic HPV vaccine
44. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope
45. Induction of anti-tumour immunity by suicide-gene-modified HPV-16-transformed hamster cells
46. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens
47. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen